Natasha Lewis
Family · Baton Rouge, LANPI 1639503550
Payments from drug & device makers
Across 236 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$655
- Fresenius USA Marketing, Inc.$594
- Otsuka America Pharmaceutical, Inc.$495
- Bayer$431
- Calliditas Therapeutics US Inc.$261
- OPKO Pharmaceuticals, LLC$224
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,68898%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $655 |
| Fresenius USA Marketing, Inc. | 29 | $594 |
| Otsuka America Pharmaceutical, Inc. | 27 | $495 |
| Bayer | 22 | $431 |
| Calliditas Therapeutics US Inc. | 12 | $261 |
| OPKO Pharmaceuticals, LLC | 13 | $224 |
| Mallinckrodt Hospital Products Inc. | 11 | $219 |
| Sanofi | 8 | $209 |
| Novartis | 8 | $205 |
| Vifor Pharma, Inc. | 10 | $198 |
| Akebia Therapeutics Inc | 8 | $192 |
| Amgen(2 entities) | 8 | $179 |
| Lilly USA, LLC | 9 | $158 |
| Aurinia Pharma U.S., Inc. | 6 | $121 |
| Medtronic | 2 | $104 |
| Nxstage Medical, Inc. | 2 | $92 |
| Daiichi Sankyo Inc. | 5 | $80 |
| Travere Therapeutics, Inc. | 4 | $73 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $68 |
| ANI Pharmaceuticals, Inc. | 3 | $49 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Ardelyx, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Cormedix Inc. | 1 | $15 |
How this compares
$4,787 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 172 | $438,329 |
| AuryxiaFerric Citrate | 118 | $245,076 |
| XphozahTenapanor Hcl | 25 | $104,139 |
| VeltassaPatiromer Calcium Sorbitex | 38 | $33,882 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $33,881 |
| JardianceEmpagliflozin | 47 | $30,081 |
| KerendiaFinerenone | 25 | $18,546 |
| Lanthanum Carbonate | 20 | $18,512 |
| RayaldeeCalcifediol | 12 | $14,176 |
| FarxigaDapagliflozin Propanediol | 21 | $13,991 |
| Sevelamer Carbonate | 121 | $13,848 |
| Clonidine | 20 | $1,989 |
| Hydralazine Hcl | 104 | $1,363 |
| Losartan Potassium | 146 | $897 |
| Doxazosin Mesylate | 63 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $594 | $438,329172 claims |
| Akebia Therapeutics IncAuryxia | $192 | $245,076118 claims |
| AstraZenecaLokelma, Farxiga | $655 | $47,87162 claims |
| Boehringer IngelheimJardiance | $21 | $30,08147 claims |
| BayerKerendia | $431 | $18,54625 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $224 | $14,17612 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $49 | $39424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Baton Rouge
- Elidia DewittBaton Rouge$108K
- Ghenet GhebretatiosBaton Rouge$91K
- Heather SullivanBaton Rouge$32K
- Randee KidderBaton Rouge$30K
- Dionne BellBaton Rouge$25K
- Jennifer LittleBaton Rouge$21K
- Tracy ParkerBaton Rouge$19K
- Celeste WaguespackBaton Rouge$18K
- Kristen VillarBaton Rouge$18K
- Sharon JacksonBaton Rouge$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.